---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-23-003950"
form_type: "8-K"
ticker: null
cik: "0000910267"
company_name: "TITAN PHARMACEUTICALS INC"
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T07:05:38.691942+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Titan Pharmaceuticals receives Nasdaq extension to Oct 2, 2023 to regain compliance with $2.5M equity requirement

## Summary
- Stockholders' equity reported at $1.363M, below Nasdaq's $2.5M minimum.
- Nasdaq grants 180-day extension to October 2, 2023 to demonstrate compliance.
- Company submitted a compliance plan on May 22, 2023.
- Failure to comply by Oct 2 or upon filing 2023 10-K may lead to delisting.
- Delisting would reduce liquidity, market price, and access to financing.

## SEC filing metadata
- accession: 0001829126-23-003950
- form_type: 8-K
- cik: 0000910267
- company_name: TITAN PHARMACEUTICALS INC
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/0001829126-23-003950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/titanpharma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-23-003950
- JSON: https://secwatch.observer/filing/0001829126-23-003950.json
- Plain text: https://secwatch.observer/filing/0001829126-23-003950.txt

## Key facts
- Listing & Compliance Notices
  TITAN PHARMACEUTICALS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: that a listed company’s stockholders’ equity be at least $2,500,000 (the “Stockholders’ Equity Requirement”). In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy the Stockholders’ Equity Requirement. The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement
  evidence_url: https://www.sec.gov/Archives/edgar/data/910267/000182912623003950/0001829126-23-003950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.